TABLE 2.

HIV Test Results Obtained at Reference Laboratories and turnaround time for Results in the NAT Referral Program, US, 2016–2019

	Year*
	2016–2017	2017–2018	2018–2019
No. submitting laboratories	27	28	29
HIV-1 NAT
No. eligible specimens† received and tested at reference laboratories	547	541	643
No. HIV-1 NAT reactive (% of specimens tested)	77 (14%)	84 (16%)	73 (11%)
HIV-2 NAT
No. eligible specimens‡ received and tested at reference laboratories	17	11	24
No. HIV-2 NAT reactive	0	0	0
TAT: median, d
Specimen collection to receipt in submitting laboratory	1	1	1
Receipt in submitting laboratory to shipment to reference laboratory	6	5	4
Shipment to reference laboratory to receipt in reference laboratory	1	1	1
Receipt in reference laboratory to HIV-1 NAT performed and reported	1	1	1
Specimen collection to HIV-1 NAT reported	10	9	9
HIV-1 NAT performed to HIV-2 NAT performed and reported	13	19	10.5
Specimen collection to HIV-2 NAT reported	22	27	22
Specimen collection to HIV-1 NAT, % within 1 wk	18%	21%	25%
Specimen collection to HIV-1 NAT, % within 2 wk	73%	84%	87%

^*Specimens tested in reference laboratories from July 1 to June 30 of indicated years.

^†Either (1) HIV-1/2 antibody or HIV Ag/Ab reactive (repeatedly) and supplemental antibody negative or indeterminate or (2) BioPlex HIV-1 Ag reactive (repeatedly) only.

^‡Either (1) HIV-1/2 antibody or HIV Ag/Ab reactive (repeatedly), supplemental antibody HIV indeterminate or HIV-2 indeterminate, HIV-1 RNA not detected or (2) BioPlex HIV Undifferentiated or HIV-2 antibody reactive and supplemental antibody nonreactive.